Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer

Oumi Nakajima, Daiju Ichimaru, Yasuo Urata, Toshiyoshi Fujiwara, Tomohisa Horibe, Masayuki Kohno, Koji Kawakami

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

We previously reported that telomerase-specific replication-component adenovirous, Telomelysin (OBP-301) has cytotoxic activity to the YCUT892, KCCT873, KCCT891, KCCL871, YCUM862, HN12, and KCCOR891 cell lines in vitro, and investigated the association between cytotoxic activity and adenoviral receptor expression. In this study, we evaluated the most appropriate way to administer telomelysin (OBP-301) in the treatment of squamous cell carcinoma of the head and neck (SCCHN), and assessed the effect of OBP-301 in large subcutaneous KCCT873 human SCCHN tumors in immunodeficient mice. We also compared antitumor responses following three intratumoral (i.t.) injections of OBP-301 given daily, every 2 days or weekly. To investigate the mechanism of the antitumor effect, we evaluated cellular infiltration in treated tumors. OBP-301 showed remarkable antitumor activity against large KCCT873 tumors, and three treatment schedules produced similar antitumor effects. The weekly regimen also significantly reduced the growth of large tumors. Immunochemistry revealed that macrophages, but not natural killer cells, were responsible for tumor regression. A regimen of three weekly injections of OBP-301 has remarkable antitumor effects against large KCCT873 tumors. These results may provide a new platform for treating patients with localized SCCHN.

Original languageEnglish
Pages (from-to)1039-1043
Number of pages5
JournalOncology reports
Volume22
Issue number5
DOIs
Publication statusPublished - 2009

Keywords

  • Adenovirus
  • OBP-301
  • Squamous cell carcinoma of the head and neck
  • Telomelysin
  • Telomerase

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer'. Together they form a unique fingerprint.

Cite this